Breast Cancer Therapeutics Pipeline Analysis Market Breast Cancer Therapeutics Pipeline Analysis Market : ToC


Breast Cancer Therapeutics Pipeline Analysis Market

Breast Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • Rep Id : TMRGL5678
  • Published On : Nov 2015
  • No. of Pages : 88
  • Category : Pharmaceutical


1 Preface
    1.1 Report Description
    1.2 Market Segmentation
    1.3 Research Methodology

2 Executive Summary
    2.1 Global Breast Cancer Therapeutics: Market Snapshot
    2.2 Global Breast Cancer Therapeutics Market Share, by Geography, 2014 & 2023(Value %)
    2.3 Global Breast Cancer Therapeutics Market, by Drug Class, 2014  & 2023 (Value %)

3 Global Breast Cancer Therapeutics Market - Market Overview
    3.1 Market Definition and Overview
    3.2 Epidemiology & High Risk Groups 
    3.3 Diagnosis and Types of Breast Cancer    
    3.4 Other Breast Cancer Therapies
    3.5 Market Dynamics
         3.5.1 Drivers
                3.5.1.1 Higher Incidence Rate
                3.5.1.2 Demographic Transition
                3.5.1.3 Rising Prevalence Of Obesity
                3.5.1.4 Diagnostic Screening Programs
                3.5.1.5 Increase in Private Health Insurance Plans: 
         3.5.2 Restraints
                3.5.2.1 Generic Drugs: Substitute Branded Drugs
                3.5.2.2 Intense Competition: Fall in Prices
                3.5.2.3 Access barriers due to high drug costs
                3.5.2.4 Absence of Social Health Insurance
                3.5.2.5 Serious Side Effects of Breast Cancer Therapeutics
                3.5.2.6 Countries Lacking Women Empowerment
                3.5.3.7 Newer medication options
         3.5.3 Opportunities
                3.5.3.1 Potential Growth of Domestic Pharmaceutical Companies
                3.5.3.2 Combination Drug Therapy
                3.5.3.3 Technological Advancements and Robust Trends of Drug Approval
                3.5.3.4 New Companion Diagnostics Models
                3.5.3.5 Drug Therapy for Triple Negative (TNBC)
                3.5.3.6 Approval for Multiple Indications (positive & negative types) HER2 breast cancer
    3.7 Market Attractiveness Analysis– Breast Cancer Therapeutics Market, by Geography (2014) (%) 
    3.8 Competitive Landscape – Breast Cancer Therapeutics Market, by Key Players,   2014 (%)

4 Market Segmentation – By Drug Class
    4.1 Overview
    4.2 Global HER2 Inhibitors Market Revenue, 2015–2023 (US$ Mn)
         4.2.1 Herceptin (Trastuzumab)
         4.2.2 Tykerb (Lapatinib) 
         4.2.3 Perjeta (Pertuzumab) 
         4.2.4 Kadcyla (Ado-trastuzumab emtansine)
    4.3 Global Mitotic Inhibitors Market Revenue, 2015–2023 (US$ Mn)
         4.3.1 Halaven (Eribulin) 
         4.3.2 Taxotere (Docetaxel)  
         4.3.3 Ixempra (Ixabepilone)   
    4.4 Global Anti-metabolites Market Revenue, 2015–2023 (US$ Mn)
         4.4.1 Gemzar (Gemcitabine)
    4.5 Global Aromatase Inhibitors Market Revenue, 2015–2023 (US$ Mn)
         4.5.1 Femara (Leterozole)
         4.5.2 Aromasin (Exemestane)
         4.5.3 Arimidex (Anastrozole)
         4.5.4 Ibrance (Palbociclib)
         4.5.5 Afinitor (Everolimus) 
    4.6 Global Hormone Receptor Market Revenue, 2015–2023 (US$ Mn)
         4.6.1 Zoladex
         4.6.2 Faslodex 
         4.6.3  Fareston 

5 Market Segmentation – By Geography
    5.1 Introduction
    5.2 Global Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
    5.3 North America Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
         5.3.1 U.S.
         5.3.2 Canada 
    5.4 Europe Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
         5.4.1 Germany
         5.4.3 U.K.
         5.4.4 Rest of Europe
    5.5 Asia Pacific Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
         5.5.1 Japan
         5.5.2 South Korea
         5.5.3 Rest of Asia Pacific
    5.6 Rest of the World
         5.6.1 Latin America
                5.6.1.1 Brazil
                5.6.1.2 Rest of Latin America
         5.6.2 Middle East and Africa

6 Recommendations

7 Company Profiles
    7.1 AstraZeneca plc
    7.2 Eisai Co., Ltd.
    7.3 Eli Lilly and Company
    7.4 F. Hoffmann-La Roche Ltd.
    7.5 GlaxoSmithKline plc    
    7.6 Novartis International AG
    7.7 Pfizer, Inc.
    7.8 Puma Biotechnology, Inc.
    7.9 Sanofi S.A.
    7.10 Teva Pharmaceutical Industries Ltd.